Navigation Links
Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
Date:11/1/2013

PALO ALTO, Calif., Nov. 1, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) is pleased to announce that it has treated the final patient of its Phase I/IIa clinical trial for ReJoin™, a human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.

The clinical trial is conducted by Shanghai's Renji Hospital, a tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine. As previously reported, the interim analysis of the trial demonstrated that patients had a clinically meaningful reduction in pain and increase in mobility, with a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events were reported for the duration of the trial.

Full data analysis by FuDan Medical University Department of Biostatistics will be carried out in the next four to six weeks and the final report of the trial will be announced before the end of the year.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and
'/>"/>

SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
2. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
3. Decellularized mouse heart beats again after regenerating with human heart precursor cells
4. Cellular Dynamics International Announces Launch of Initial Public Offering
5. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
6. Cellular Therapy and Cord Blood 2013 Market Report
7. Cellular Biomedicine Group Announces Appointment of Corporate Controller
8. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
9. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
10. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
11. Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Potential Future Application of Stem Cells as a ... Treatment for Diabetes ... Nature Biotechnology, SAN DIEGO, Feb. 20 Novocell, Inc., a stem cell,engineering ... cells can be turned into pancreatic cells,capable of producing insulin in mice. The ...
... PPD, Inc. (Nasdaq:,PPDI) today announced its plans to begin ... common stock may be purchased from time to time,in the ... a share repurchase program in,view of the current price at ... balance sheet and its ability to generate cash,as well as ...
... Rotarix Would be the Only Vaccine Indicated to Prevent, ... Circulating Types, Offering, Completion of the Vaccination by ... GAITHERSBURG, Md. and PHILADELPHIA, Feb. 20 ,GlaxoSmithKline (NYSE: ... Drug,Administration,s (FDA) Vaccines and Related Biological Products Advisory,Committee (VRBPAC) ...
Cached Biology Technology:Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice 2Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice 3PPD Announces Plan to Repurchase Shares of its Common Stock 2GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral) 2GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral) 3GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral) 4
(Date:7/25/2014)... scientists from 25 countries and 35 states will ... the Genetics Society of America (GSA) next week ... conference will feature close to 500 presentations (including ... including gene expression and regulation, functional genomics, chemical ... and a variety of diseases. , Of ...
(Date:7/25/2014)... pleiotropic factor characterized by the existence of numerous ... confer to the protein deeply different characteristics. NRG1 ... occurring during development and the different phases occurring ... axon regrowth, remyelination and target reinnervation, Researchers at ... the soluble NRG1 upregulation observed in Schwann cells ...
(Date:7/25/2014)... KANSAS CITY, MOResearchers at the Stowers Institute for ... classes of pheromone receptors, and found pheromones crucial to ... one class of receptors helps a male mouse detect ... other class of receptors lets him know if the ... sets of pheromones are critical to trigger mating. Stowers, ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2It takes two to court 2It takes two to court 3
... loss of dopamine neurons is a hallmark of many ... Stem cell biology and regenerative medicine offer novel therapies ... the online open-access journal PLoS Biology Dr. Raja Kittappa, ... McKay show that the transcription factor FOXA2 plays a ...
... invasive plant species is complex, to say the least. ... create conditions that promote population explosions of invasive plants, ... to the ecosystems they inhabit. On the other, fire ... growth. A new general technical report published by ...
... New microscopic pictures show the first-ever physical evidence ... (CF) disease. Researchers at the University of Alabama ... protein called epithelial sodium channel, or ENaC. Both proteins ... exactly what role each plays is unclear. ...
Cached Biology News:Cystic fibrosis proteins photographed interacting 2
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: